ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2010
Statins for community-acquired pneumonia: current state of the science.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Trial
- Reducing the complications from community acquired pneumonia: a review.Journal of thoracic disease · 2026Review
- Effects of statins on clinical outcomes in hospitalized patients with community-acquired pneumonia.The Journal of international medical research · 2020Article
- Association of Statin Use With the In-Hospital Outcomes of 2019-Coronavirus Disease Patients: A Retrospective Study.Frontiers in medicine · 2020Article
- HDL-c levels predict the presence of pleural effusion and the clinical outcome of community-acquired pneumonia.SpringerPlus · 2016Article
- Advances in the prevention, management, and treatment of community-acquired pneumonia.F1000Research · 2016Review
- Inhibitory effects of simvastatin on staphylococcus aureus lipoteichoic acid-induced inflammation in human alveolar macrophages.Clinical and experimental medicine · 2014Article
- Effect of statin therapy in the outcome of bloodstream infections due to Staphylococcus aureus: a prospective cohort study.PloS one · 2013Article
- Clinical features, etiology, and outcomes of community-acquired pneumonia in patients with diabetes mellitus.Medicine · 2013Article
- Effect of statin use on outcomes of adults with candidemia.PloS one · 2013Article
- Modulation of bacterial pathogenesis by oppressive aging factors: insights into host-pneumococcal interaction strategies.ISRN inflammation · 2012Review
- Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin.Annals of clinical microbiology and antimicrobials · 2012Article
- Statins and influenza: can we move forward?The Journal of infectious diseases · 2012Article
- Do aspirin and other antiplatelet drugs reduce the mortality in critically ill patients?Thrombosis · 2012Article
- Simvastatin is protective during Staphylococcus aureus pneumonia.Current pharmaceutical biotechnology · 2011Article
- Understanding the potential role of statins in pneumonia and sepsis.Critical care medicine · 2011Article
- Marked reduction in 30-day mortality among elderly patients with community-acquired pneumonia.The American journal of medicine · 2011Article
- Effect of statins on outcomes in immunosuppressed patients with bloodstream infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In spite of the many advances in the diagnosis and management of community-acquired pneumonia (CAP), the mortality associated with this infection remains high. In recent years scientific evidence has emerged that shows that an excessive inflammatory response is a major cause of unfavorable outcome in patients with CAP, especially in the first few days. The use of immunomodulation appears to be an appealing option for improving prognosis in CAP. It has recently been demonstrated that statins have immunomodulatory, antioxidative and anticoagulant effects, and the beneficial effects of these drugs in sepsis have been discussed. Experimental studies have shown their effect in the modulation of the cytokine cascade and in the organization of the immunological response to respiratory infection. Most observational studies published to date support the idea that the use of statins may improve the prognosis of CAP. Randomized controlled trials are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.